NewcelX Strengthens Mazindol's Path with Major Publication and Strategic Advancements

NewcelX Strengthens Its Stance on Mazindol

NewcelX Ltd., a company in the clinical-stage of biopharmaceutical development, has recently taken significant strides in its strategic endeavors concerning Mazindol, a medication with promising therapeutic potential for various central nervous system (CNS) disorders. The company has announced the publication of a peer-reviewed scientific article titled, "Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential," which has been featured in Clinical Drug Investigation, a reputable journal under Springer Nature.

This publication serves as a crucial turning point, not just for NewcelX, but also for stakeholders interested in the licensure and acquisition of the Mazindol asset. The peer-reviewed validation provides a stronger clinical and mechanistic profile of Mazindol ER, thus enhancing the credibility of the discussions NewcelX is currently engaged in regarding potential licensing and acquisition. Management at NewcelX asserts that this external validation will bolster buyer confidence, expedite due diligence, and promote value recognition in ongoing negotiations.

Currently, NewcelX is pursuing advanced discussions with various potential partners to assess opportunities surrounding the Mazindol product line. These negotiations are being managed within a structured environment aimed at optimizing transaction terms. The driving objective for NewcelX is to finalize a strategic transaction that ensures the crystallization of Mazindol ER's intrinsic value, consequently delivering significant returns to both CVR holders and shareholders alike.

The recent publication corroborates the profound 20-year research commitment that supports the development of Mazindol ER. With roots tracing back to 2006, this product is poised to cater to large, underserved markets, including conditions such as narcolepsy, ADHD, and substance use disorders. NewcelX is enthused that the peer-reviewed nature of this publication raises the profile of Mazindol ER, significantly boosting its commercial viability within strategic discussions.

Dr. Eric Konofal, who heads NewcelX's DOXA Program, emphasizes the significance of this publication as a culmination of two decades of consistent research efforts. He stated, "This milestone publication underscores our unwavering dedication to advancing Mazindol ER as a groundbreaking therapeutic option for CNS disorders."

Ronen Twito, Executive Chairman and CEO of NewcelX, further commented on the company's perspective regarding its ambitious goals: “We aim to convert the scientific strength of Mazindol ER into strategic and financial results. The peer-reviewed publication substantially fortifies our negotiating strength as we engage with interested parties to unlock the complete commercial potential of this asset.”

As NewcelX continues to carve out its niche within the biopharmaceutical sector geared towards innovative solutions for Type 1 Diabetes and CNS disorders, this key milestone is indicative of the company's broader ambitions and its commitment to advancing transformative healthcare solutions. Stakeholders and industry observers will be keenly watching how these developments unfold, particularly with respect to how they impact the company's future trajectories and the overall marketplace dynamics.

For further details about NewcelX and its offerings, please visit www.newcelx.com.